Spring Bank Pharmaceuticals to Present HBV and HCV Results with SB 9200 at EASL 2015

MILFORD, Mass., April 13, 2015 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced two poster presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections, at The International Liver Congress™ 2015, 50^th annual meeting of the European Association for the Study of the Liver (EASL), taking place April 22-26, in Vienna, Austria.

"We are very pleased to have been selected to present our HBV preclinical data and HCV Phase I data at the upcoming EASL meeting," said Radhakrishnan (Kris) Iyer, Ph.D., Chief Scientific Officer of Spring Bank.  "This congress affords us the opportunity to highlight our drug development programs in two difficult-to-treat viral infections to the worldwide medical and scientific communities."

Details of Spring Bank's presentations are below:

Poster Presentation

Title: Antiviral Efficacy and Induction of Host Immune Responses with SB 9200, an Oral Prodrug of the Dinucleotide SB 9000, in the Woodchuck Model of Chronic Hepatitis B Virus (HBV) Infection 
Date and Time: Saturday, April 25, 2015, 12:30 pm – 1:00 pm CEST 
Location: Hall B ePoster Area 
Abstract Number: P0636 
Session Info: Viral hepatitis: Hepatitis B & D – c. Clinical (Therapy, new compounds, resistance) 

An oral presentation of the poster will also be made by Dr. Stephan Menne, Research Associate Professor at the Department of Microbiology & Immunology, Georgetown University Medical Center
Date and Time: Saturday, April 25, 2015, 12:30 pm – 1:00 pm CEST
Location: Hall B ePoster Area
ePoster screen: C-01 

Late Breaker

Title: SB 9200, A Novel Immunomodulator for Patients with Viral Hepatitis: Phase 1 MAD Study in patients with Hepatitis C Virus (HCV) Infection 
Date and Time: Saturday, April 25, 2015, 3:30 pm – 4:00 pm CEST 
Location: Hall B ePoster Area 

About European Association for the Study of the Liver (EASL)

Since 1966, when the association was founded, EASL has continued to grow from a small organisation that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policies. For more information about EASL, please visit https://ilc-congress.eu/.

About SB 9200

SB 9200, derived from Spring Bank's proprietary Small Molecule Nucleic Acid Hybrid (SMNH) technology platform, is a novel anti-viral agent that uniquely acts by modulating the host immune response to viral infections through activation of the intracellular sentinel proteins RIG-I and NOD2. SB 9200 is being developed for the treatment of chronic hepatitis B and C and other viral infections.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is a clinical stage biopharmaceutical company. Based on its proprietary SMNH chemistry platform, Spring Bank is developing a pipeline of products representing a new class of pharmaceuticals with a wide range of applications. These rationally designed molecules combine the selectivity of naturally occurring nucleotides with the drug-like properties of classical pharmaceuticals.  The SMNHs have the properties of oral delivery, good pharmacokinetic profile, low side effects and ease of manufacture. The Company's most advanced clinical candidate, SB 9200, is a potential breakthrough drug for the treatment for HBV, HCV and other viral diseases. SB 9200 has a novel mechanism of action that involves modulation of the host immune response in the presence of viral infection. 

Note Regarding NIH-Funded Research

Certain studies mentioned in this press release were partly supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01AI094469 and NIAID contract laboratories. The content of this press release is solely the responsibility of Spring Bank Pharmaceuticals and does not necessarily represent the official views of the National Institutes of Health.

Contact: 

Douglas J. Jensen 
President and Chief Executive Officer, Spring Bank Pharmaceuticals 
(508) 473-5993 x105

Matthew Haines / Maeve Conneighton 
Argot Partners 
(212) 600-1902 
[email protected] 
[email protected]

SOURCE Spring Bank Pharmaceuticals, Inc.

Related Links

http://www.springbankpharm.com